📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
2 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
BEARISH
TOTAL VIEWS
97
CAPR Latest News & AI Sentiment Analysis
2 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 9 ARTICLES
Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) – Lead Plaintiff Deadline is September 28, 2026
CAPR faces a securities class action lawsuit filed by Kaplan Fox, a litigation firm specializing in shareholder disputes. The lead...
Morning Market Movers: WETO, CAPR, AKAN, DAAQ See Big Swings
This premarket note catalogs early trading activity in four micro-cap or lower-liquidity securities without identifying fundamental...
Kaplan Fox Alerts Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) with Significant Losses to a Securities Class Action Deadline on September 28, 2026
Capricor Therapeutics (CAPR) faces a securities class action lawsuit with a filing deadline of September 28, 2026, as announced by...
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Who Suffered Losses to a Securities Class Action – Deadline is September 28, 2026
CAPR is subject to a securities class action lawsuit, with Kaplan Fox alerting investors of losses and establishing a September 28, 2026...
Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026
Capricor Therapeutics (CAPR) has experienced significant shareholder losses, prompting legal action notification from law firm Kaplan...
Capricor Therapeutics Stock Tanks 54% Over FDA Panel's Negative Vote On Deramiocel Effectiveness
Capricor Therapeutics (CAPR) experienced a severe single-day collapse following an FDA advisory committee's rejection of clinical...
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
The Lancet publication of HOPE-3 trial data for Capricor Therapeutics' (CAPR) deramiocel represents a significant validation milestone...
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR)
Capricor Therapeutics (CAPR) faces a significant headwind following a downgrade to Sell, driven by FDA efficacy doubts surrounding its...
Capricor Stock Tanks On FDA AdCom Notes - What Investors Should Know (NASDAQ:CAPR)
Capricor (CAPR) experienced a sharp 65% equity decline following negative FDA Advisory Committee feedback on deramiocel's efficacy...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice